Hepatitis B vaccination and multiple sclerosis: a data mining perspective.
作者信息
Hauben Manfred, Sakaguchi Motonobu, Patadia Vaishali, M Gerrits Charles
出版信息
Pharmacoepidemiol Drug Saf. 2007 Aug;16(8):943-5. doi: 10.1002/pds.1420.
DOI:10.1002/pds.1420
PMID:17636551
Abstract
摘要
相似文献
1
Hepatitis B vaccination and multiple sclerosis: a data mining perspective.
Pharmacoepidemiol Drug Saf. 2007 Aug;16(8):943-5. doi: 10.1002/pds.1420.
2
The role of databases in drug postmarketing surveillance.
Pharmacoepidemiol Drug Saf. 2001 Aug-Sep;10(5):407-10. doi: 10.1002/pds.615.
3
Use of health care databases in pharmacoepidemiology.
Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):311-3. doi: 10.1111/j.1742-7843.2006.pto_368.x.
4
Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis.
Eur J Gastroenterol Hepatol. 2007 Nov;19(11):934-41. doi: 10.1097/MEG.0b013e3282efa502.
5
The quantification of drug risks in practice.
WHO Reg Publ Eur Ser. 1993;45:79-95.
6
Hepatitis B vaccine and risk of multiple sclerosis.
Pharmacoepidemiol Drug Saf. 2007 Jun;16(6):705-7, author reply 707-8. doi: 10.1002/pds.1408.
7
8
[French system of drug surveillance].
Bull Acad Natl Med. 1998;182(7):1383-91; discussion 1392-3.
9
Hepatitis B vaccine and risk of multiple sclerosis.
Expert Rev Vaccines. 2002 Dec;1(4):461-6. doi: 10.1586/14760584.1.4.461.
10
Estimating national drug consumption using data at different points in the pharmaceutical supply chain.
Pharmacoepidemiol Drug Saf. 2006 Oct;15(10):754-7. doi: 10.1002/pds.1309.
引用本文的文献
1
The first steps towards the era of personalised vaccinology: predicting adverse reactions.
Pharmacogenomics J. 2015 Jun;15(3):284-7. doi: 10.1038/tpj.2014.57. Epub 2014 Oct 7.
2
Vaccination against infection in patients with multiple sclerosis.
Nat Rev Neurol. 2012 Jan 24;8(3):143-51. doi: 10.1038/nrneurol.2012.8.
Zotero 插件